SEC Tracker
Get the app

First Tracks Biotherapeutics TRAX

First Tracks Biotherapeutics reported Q3 2026 losses.

Securities offering

Form
424B3
Filed
Importance
Routine
  1. Net loss of $31.4 million for Q3 2026.
  2. Cash and cash equivalents decreased to $155.6 million as of September 30, 2026.
  3. Research and development expenses were $23.8 million for Q3 2026.

Written from the 424B3 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when First Tracks Biotherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. America Great Health AAGH
  2. AbbVie ABBV public float $325.1B, Jun 30, 2025
  3. Abeona Therapeutics ABEO public float $273M, Jun 30, 2025
  4. Abbott Laboratories ABT public float $232.2B, Jun 30, 2025
  5. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.